Company Interview / Little Green Pharma's growing expansion

Paul Long CEO of Little Green Pharma (ASX:LPG) discusses the company's acquisition of Health House. Paul highlights Health House's long-standing reputation as a medicinal cannabis distributor in Australia. He states the move is a promising addition to Little Green Pharma's supply chain, aiming to boost revenue and margin growth

Paul mentions the acquisition price of $375,000 and notes it was initially priced much higher. He views this as an opportunity to strengthen their integrated supply chain amidst market changes. He shares that Little Green Pharma (ASX:LPG) is well-positioned with significant tangible assets in Australia and Europe, and is exploring further consolidation opportunities.

Looking towards future growth, Paul focuses on the significant potential in the European market, particularly in Germany. Little Green Pharma (ASX:LPG) targets high-entry benchmark markets like France and Italy, and also sees potential in Asia, particularly Japan. The strategy revolves around building market share in robust markets like Australia, Germany, and the UK.